Published today, Deprescribing in Patients with Cardiovascular (CV) Disease Experiencing Polypharmacy A Scientific Statement from the American Heart Association. professional.heart.org/en/sc… Guideline-directed medical therapy in CV care often requires multiple medications across coexisting conditions and comorbidities, making polypharmacy common in routine practice. 📷 Optimal prescribing ✍🏼 @robdeedo @adambress @quin_denfeld @PaulDobesh @ParagGoyalMD

Polypharmacy is common in cardiovascular care because guideline-directed treatment often requires multiple medications across coexisting conditions and comorbidities, increasing medication burden. professional.heart.org/en/sc… Deprescribing is a proactive, patient-centered strategy to reduce medication burden and can be effective not only after adverse drug events, but also when polypharmacy, prescribing cascades, poor adherence, or changing goals of care warrant reassessment. Safe deprescribing requires a structured, multidisciplinary approach that uses systematic review tools, shared decision-making, careful tapering, and close follow-up to align treatment with patient goals while minimizing adverse events. ✍🏼 @robdeedo @adambress @quin_denfeld @PaulDobesh @ParagGoyalMD